Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Stock-Based-Compensation" stands at 1.28 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the highest value at least since 03/31/2012, the period currently displayed.
Johnson & Johnson's third quarter result of 0.347 Billion USD for the item "Stock Based Compensation" represents a decrease of -15.37 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 0.347 Billion USD for the item "Stock Based Compensation" represents an increase of 17.63 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 1.28 Billion USD for the item "Stock Based Compensation" represents an increase of 4.22 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 14.96 percent compared to the value the year prior.
The 1 year change in percent is 14.96.
The 3 year change in percent is 12.54.
The 5 year change in percent is 27.66.
The 10 year change in percent is 55.89.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Stock Based Compensation | 905,699,262,464.00 |
![]() | AbbVie Inc - Stock Based Compensation | 399,570,305,024.00 |
![]() | Roche Holding AG - Stock Based Compensation | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Stock Based Compensation | 280,205,508,085.11 |
![]() | Novartis AG - Stock Based Compensation | 255,096,620,580.91 |